Phenothiazines and structurally related compounds as modulators of cancer multidrug resistance

Current Drug Targets

Volumn 7, Issue 9, 2006, Pages 1123-1134

  Tsakovska, I ^a,b   Pajeva, I ^a  

^a CENTRE OF BIOMEDICAL ENGINEERING   (Bulgaria)

^b JOINT RESEARCH CENTRE   (Italy)

Author keywords

Cancer MDR; Membrane activity; Pgp; Phenothiazines; QSAR

Indexed keywords

BUTACLAMOL; CALMODULIN INHIBITOR; CHLORPROMAZINE; CLOMIPRAMINE; CLOPENTHIXOL; COLCHICINE; CYCLOSPORIN A; DACTINOMYCIN; DAUNORUBICIN; DIPYRIDAMOLE; DOXORUBICIN; FLUPENTIXOL; FLUPHENAZINE; GLYCOPROTEIN P; IMIPRAMINE; MEFLOQUINE; MEMBRANE PHOSPHOLIPID; MEPACRINE; PHENOTHIAZINE DERIVATIVE; PROMETHAZINE; QUINIDINE; TAMOXIFEN; THIORIDAZINE; THIOXANTHENE DERIVATIVE; TRIFLUOPERAZINE; TRIFLUPROMAZINE; UNINDEXED DRUG; VERAPAMIL; VINBLASTINE; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER RESISTANCE; DRUG BINDING SITE; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PHYSICAL CHEMISTRY; PROTEIN INTERACTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; TUMOR CELL;

ANIMALS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; PHENOTHIAZINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33748484255     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945006778226660     Document Type: Review

References (106)

1. Gottesman, M.M. (1993) Cancer Res., 53 (4), 747-754.
2. Ambudkar, S.; Dey, S.; Hrycyna, C.; Ramachandra, M.; Pastan, I. and Gottesman, M. (1999) Annu. Rev. Pharmacol. Toxicol, 39, 361-398.
3. Tsuruo, T.; Iida, H.; Tsukagoshi, S. and Sakurai, Y. (1981) Cancer Res., 41(5), 1967-1972.
4. Ford, J. and Hait, W. N. (1990) Pharmacol. Rev., 42 (3), 155-199.
5. Kellen, J. (1993) Anticancer Res., 13 (4), 959-961.
6. Ford, J. M. (1995) Hematol./Oncol. Clin. North Am., 9 (2), 337-361.
7. Motohashi, N.; Kawase, M.; Saito, S, and Sakagami, H. (2000) Curr. Drug Targets, 1 (3), 237-245.
8. Tsuruo, T.; Iida, H.; Tsukagoshi, S. and Sakurai, Y. (1982) Cancer Res., 42 (11), 4730-4733.
9. Ganapathi, R. and Grabowski, D. (1983) Cancer Res., 43 (8), 3696-3699.
10. Akiyama, S.; Shiraishi, N.; Kuratomi, Y.; Nakagawa, M. and Kuwano, M. (1986) J. Natl. Cancer Inst., 76 (5), 839-844.
11. Ganapathi, R.; Grabowski, D.; Turinic, R. and Valenzuela, R. (1984) Eur. J. Cancer Clin. Oncol., 20 (6), 799-806.
12. Ford, J.M.; Prozialeck, W.C. and Hait, W.N. (1989) Mol. Pharmacol., 35 (1), 105-115.
13. Ford, J.M.; Bruggemann, E.P.; Pastan, I.; Gottesman, M.M. and Hait, W.N. (1990) Cancer Res., 50 (6), 1748-1756.
14. Seydel, J.K. and Wiese, M. (2002) in Drug-Membrane Interactions, (Mannhold, R., Kubinyi, H. and Folkers, G., Eds.), Wiley-VCH, Weinheim, pp. 245-289.
15. Higgins, C.F. (1992) Annu. Rev Cell. Biol, 8, 67-113.
16. Gottesman, M.M. and Pastan, I. (1993) Annu. Rev. Biochem., 62, 385-427.
17. Higgins, C.F.; Callaghan, R.; Linton, K.J.; Rosenberg, M.F. and Ford, R.C. (1997) Semin. Cancer Biol., 8 (3), 135-142
18. Rosenberg, M.F.; Callaghan, R.; Modok, S.; Higgins, C.F. and Ford, R.C. (2004) J. Biol. Chem., 280 (4), 2857-2862.
19. Wiese, M. and Pajeva, I.K. (2001) Curr. Med. Chem., 8 (6), 685-713.
20. Safa, A.R. (2004) Curr. Med. Chem. Anti-Canc. Agents, 4 (1), 1-17.
21. Martin, C.; Berridge, G.; Higgins, C.F.; Mistry, P.; Charlton, P. and Callaghan, R. (2000) Mol. Pharmacol., 58 (3), 624-632.
22. Shen, D.W.; Cardarelli, C.; Hwang, J.; Cornwell, M.; Richert, N.; Ishii, S.; Pastan, I. and Gottesman, M.M. (1986) J. Biol. Chem., 261 (17), 7762-7770.
23. Fojo, A., Akiyama, S., Gottesman, M.M. and Pastan, I. (1986) Cancer Res., 45 (7), 3002-3007.
24. Scala, S.; Akhmed, N.; Rao, U.S.; Paull, K.; Lan, L.B.; Dickstein, B.; Lee, J.S.; Elgemeie, G.H.; Stein, W.D. and Bates, S.E. (1997) Mol. Pharmacol., 51(6), 1024-1033.
25. Safa, A.R., Agresti, M., Bryk, D. and Tamai, I. (1994) Biochemistry, 33 (1), 256-265.
26. Safa, A.R.; Agresti, M.; Tamai, I.; Mehta, N.D. and Vahabi, S., (1990) Biochem. Biophys. Res. Commun., 166 (1), 259-266.
27. Greenberger, L.M.; Yang, C.P.; Gindin, E. and Horwitz, S.B. (1990) J. Biol. Chem., 265 (8), 4394-4401.
28. Safa, A. (1998) in Methods in Enzymology, Vol. 292 (Ambudkar, S. and Gottesman, M., Eds.), Academic Press, San Diego, pp.289-307.
29. Dey, S.; Ramachandra, M.; Pastan, I.; Gottesman, M.M. and Ambudkar, S.V. (1997) Proc. Natl. Acad. Sci. USA, 94 (20), 10594-10599.
30. Maki, N.; Hafkemeyer, P. and Dey S. (2003) J. Biol. Chem., 278 (20), 18132-18139.
31. Dey, S.; Hafkemeyer, P.; Pastan, I. and Gottesman, M.M. (1999) Biochemistry, 38 (20), 6630-6639.
32. Szabo, D. and Molnar, J. (1998) Anticancer Res., 18 (4C), 3039-3044.
33. Molnar, J.; Molnar, A.; Mucsi, I.; Pinter, O.; Nagy, B.; Varga, A. and Motohashi, N. (2003) In Vivo, 17 (2), 145-149.
34. Hamada, H. and Tsuruo, T. (1988) J. Biol Chem., 263 (3), 1454-1458.
35. Ayesh S.; Shao Y.M. and Stein W.D. (1996) Biochim. Biophys. Acta, 1316 (1), 8-18.
36. Liu, R. and Sharom, F.J. (1996) Biochemistry, 35 (36) 11865-11873.
37. Liu, R., Siemiarczuk, A. and Sharom, F.J. (2000) Biochemistry, 39 (48), 14927-14938.
38. Motohashi, N.; Kurihara, T.; Kawase, M.; Hever, A.; Tanaka, M.; Szabo, D.; Nacsa, J.; Yamanaka, W.; Kerim, A. and Molnar, J. (1997) Anticancer Res., 17 (5A), 3537-3543.
39. Molnar, J.; Szabo, D.; Mandi, Y.; Mucsi, I.; Fischer, J.; Varga, A.; Konig, S. and Motohashi, N. (1998) Anticancer Res., 18 (4C), 3033-3038.
40. Wesolowska, O.; Molnar, J.; Motohashi, N. and Michalak, K. (2002) Anticancer Res., 22 (5), 2863-2867.
41. Hendrich, A.B.; Wesolowska, O.; Pola, A.; Motohashi, N.; Molnar, J. and Michalak, K. (2003) Mol. Membr. Biol., 20 (1), 53-60.
42. Hendrich, A.B.; Wesolowska, O.; Motohashi, N.; Molnar, J. and Michalak, K. (2003) Biochem. Biophys. Res. Commun., 304 (2), 260-265.
43. Litman, T.; Zeuthen, T.; Skovsgaard, T. and Stein, W.D. (1997) Biochim. Biophys. Acta, 1361 (2), 159-168.
44. URL:http://www.acdlabs.com, email: robin.martinαcdlabs.com
45. Ghose, A.K. and Crippen, G.M. (1982) J. Med. Chem., 25 (8), 892-899.
46. Seydel, J.K.; Velasco, M.A.; Coats, E.A.; Cordes, H.P.; Kunz, B. and Wiese, M. (1992) Quant. Struct. Act. Relat., 11, 205-210.
47. Seydel, J.K.; Coats, E.A.; Cordes, H.P.; Wiese, M. (1994) Arch. Pharm., 327 (10), 601-610.
48. Ferte, J. (2000) Eur. J. Biochem., 267 (2), 277-294.
49. Hendrich, A.B. and Michalak, K. (2003) Curr. Drug Targets, 4 (1), 23-30.
50. Callaghan, R.; van Gorkom, L.C. and Epand, R.M. (1992) Br. J. Cancer, 66 (5), 781-786.
51. Zijlstra, J.G.; de Vries, E.G.; Muskiet, F.A.; Martini, I.A.; Timmer-Bosscha, H. and Mulder, N.H. (1987) Int. J. Cancer, 40 (6), 850-856.
52. Awasthi, S.; Sharma, R.; Awasthi, Y.C.; Belli, J.A. and Frenkel, E.P. (1992) Cancer Lett., 63 (2), 109-116.
53. Saeki, T.; Shimabuku, A.M.; Ueda, K. and Komano, T. (1992) Biochim. Biophys. Acta, 1107 (1), 105-110
54. Callaghan, R.; Stafford, A. and Epand, R.M. (1993) Biochim. Biophys. Acta, 1175 (3), 277-282.
55. Pallares-Trujillo, J.; Lopez-Soriano, F.J. and Argiles, J.M. (2000) Int. J. Oncol., 16 (4), 783-798.
56. Wadkins, R.M. and Houghton, P.J. (1993) Biochim. Biophys. Acta, 1153 (2), 225-236.
57. Chambers, T.; Zheng, B.; and Kuo, J.K. (1992) Mol. Pharmacol., 41 (6), 1008-1015.
58. Bates, S.E.; Lee, J.S.; Dickstein, B.; Spolyar, M. and Fojo, A.T. (1993) Biochemistry, 32 (35), 9156-9164.
59. Pajeva, I.K; Wiese, M.; Cordes, H.P. and Seydel, J.K. (1996) J. Cancer Res. Clin. Oncol., 122 (1), 27-40.
60. Romsicki, Y. and Sharom, F.J. (1999), Biochemistry, 38 (21), 6887-6896.
61. Seydel, J.K; Coats, E.A.; Pajeva, I.K. and Wiese, M. (1996) in Bioactive Compound Design: Possibilities for Industrial Use, (Ford, M.G.; Greenwood, R., Brooks, G.T. and Franke, R., Eds.), SCI, BIOS Sci. Publ. Ltd., Oxford, pp. 137-147.
62. Alon, N.; Busche, R.; Tummler, B. and Riordan, J.K. (1991) in Molecular and cellular biology of multidrug resistance in tumour cells, (Roninson, I.B., Ed.), Plenum, New York, London, pp. 263-276.
63. Goormaghtigh, E.; Chatelain, P.; Caspers, J. and Ruysschaert, J.M. (1980) Biochim. Biophys. Acta, 597 (1), 1-14.
64. Bell, R.M.; Burns, D.J. (1991) J. Biol. Chem., 266 (8), 4661-4664.
65. Seydel, J.K. (1991) Trends Pharmacol. Sci., 12 (10), 368-371.
66. Pajeva, I.K.; Seydel, J.K. and Wiese M. (1995) In QSAR and Molecular Modelling: Computational Tools and Biological Applications, (Sanz, F.; Giraldo, J. and Manaut, F., Eds.), Prous Science Publishers, Barcelona, pp. 131-133.
67. Pajeva, I.; Todorov, D.K. and Seydel, J. (2004) Eur. J. Pharm. Sci., 21 (2-3), 243-250.
68. Pajeva, I. and Wiese, M. (1997) Quant. Struct.-Act. Relat., 16, 1-10.
69. Wiese, M. and Pajeva, I.K. (1997) Pharmazie, 52 (9), 679-685.
70. Hendrich, A.B.; Wesolowska, O. and Michalak, K. (2001) Biochim. Biophys. Acta, 1510 (1-2), 414-425.
71. Frenzel, J.; Arnold, K. and Nuhn, P. (1978) Biochim. Biophys. Acta, 507 (2), 185-197.
72. Nerdal, W.; Gundersen, S.A.; Thorsen, V.; Hoiland, H. and Holmsen, H. (2000) Biochim. Biophys. Acta, 1464 (1), 165-175.
73. Hendrich, A.B.; Wesolowska, O.; Komorowska, M.; Motohashi, N.; Michalak, K. (2002) Biophys. Chem., 98 (3), 275-285.
74. Wesolowska, O.; Hendrich, A.B.; Motohashi, N.; Kawase, M.; Dobryszycki, P.; Ozyhar, A. and Michalak, K. (2004) Biophys. Chem., 109 (3), 399-412.
75. Motohashi, N.; Kawase, M.; Saito, S.; Kurihara, T.; Satoh, K.; Nakashima, H.; Premanathan, M.; Arakaki, R.; Sakagami, H. and Molnar, J. (2000) Int. J. Antimicrob. Agents, 14 (3), 203-207.
76. Aftab, D.T.; Ballas, L.M.; Loomis, C.R. and Hait, W.N. (1991) Mol. Pharmacol., 40 (5), 798-805.
77. Castaing, M.; Brouant, P.; Loiseau, A.; Santelli-Rouvier, C.; Santelli, M.; Alibert-Franco, S.; Mahamoud, A. and Barbe, J. (2000) J. Pharm. Pharmacol., 52 (3), 289-296.
78. Bebawy, M.; Morris, M.B. and Roufogalis, B.D. (2001) Br. J. Cancer, 85 (12), 1998-2003.
79. Syed, S.K.; Christopherson, R.I. and Roufogalis, B.D. (1998) Br. J. Cancer, 78 (3), 321-327.
80. Stein, W.D. (1997) Physiol. Rev., 77 (2), 545-590.
81. Tenforde, T.S.; Yee, J.P. and Mel, H.C. (1978) Biochim. Biophys. Acta, 511(2), 152-162.
82. Zachowski, A. and Durand, P. (1988) Biochim. Biophys. Acta, 937 (2), 411-416.
83. Sharom, F.J. (1997) Biochem. Soc. Trans., 25 (3), 1088-1096.
84. Barbieri, F.; Alama, A.; Tasso, B.; Boido, V.; Bruzzo, C. and Sparatore, F. (2003) Invest. New Drugs, 21 (4), 413-420.
85. Ramu, A. and Ramu, N. (1992) Cancer Chemother. Pharmacol., 30 (3), 165-173.
86. Motohashi, N.; Kawase, M.; Kurihara, T.; Hever, A.; Nagy, S.; Ocsocvszki, I.; Tanaka, M. and Molnar, J. (1996) Anticancer Res., 16 (5A), 2525-2532.
87. Kessel, D.; Beck, W.T.; Kukuruga, D. and Schulz, V. (1991) Cancer Res., 51 (17), 4665-4670.
88. Tsakovska, I.M. (2003) Bioorg. Med. Chem., 11 (13), 2889-2899.
89. Hait, W.N. and Aftab, D.T. (1992) Biochem. Pharmacol., 43 (1), 103-107.
90. Kodavanti, U.P. and Mehendale, H.M. (1990) Pharmacol. Rev., 42 (4), 327-354.
91. Kubinyi, H. (1990) In Comprehensive Medicinal Chemistry, Vol. 4, (Hansch, C., Ed.), Pergamon Press, Oxford, pp. 589-643.
92. Klopman, G.; Shi, L.M. and Ramu, A. (1997) Mol. Pharmacol., 52 (2), 323-334.
93. Kubinyi, H. (1993) In QSAR. Hansch Analysis and Related Approaches, Vol 1 (Mannhold, R.; Kroogsgard-Larsen, P. and Timmerman, H., Eds), VCH, Weinheim, pp. 57-62.
94. Dearden, J.C., Al-Noobi, A., Scott, A.C. and Thomson, S.A. (2003) SAR. QSAR Environ. Res., 14 (5-6), 447-454.
95. Pajeva, I. and Wiese, M. (1998) J. Med. Chem., 41 (11), 1815-1826.
96. Cramer III, R.D.; DePriest, S.A.; Patterson, D.E. and Hecht, P. (1993) In 3D QSAR in drug design. Theory methods and applications, (Kubinyi, H. Ed.), ESCOM, Leiden, pp. 443-486.
97. Tripos Inc., 1699 Hanley Road, St. Louis, MO 63144.
98. Kellog, G.E.; Semus, S.F. and Abraham, D.J. (1991) J. Comput.- Aided Mol. Des., 5, 545-552.
99. Edusoft, LC, P.O. Box 1811, Ashland, VA 23005.
100. Pajeva, I.K. and M. Wiese (2001) In Lipophilicity in Drug Disposition", P.- (Carrupt, A., Ed.), Wiley-VCH, Weinheim, Multimedia publication logP2000, file Pb04.
101. Klebe, G. (1998) in 3D QSAR in drug design. Recent Advances, Vol 3, (Kubinyi, H.; Klebe, G.; Martin; Y., Eds.), KLUWER/ESCOM, Dordrecht, pp. 87-104.
102. Pajeva, I.K. and Wiese, M. (2002) J. Med Chem., 45 (26), 5671-5686.
103. Raderer, M. and Scheithauer, W. (1993) Cancer, 72 (12), 3553-3563.
104. Murren, J.R.; Durivage, H.J.; Buzaid, A.C.; Reiss, M.; Flynn, S.D.; Carter, D. and Hait, W.N. (1996) Cancer Chemother. Pharmacol., 38 (1), 65-70.
105. Pommerenke, E.W.; Osswald, H.; Hahn, E.W. and Volm, M. (1990) Cancer Lett., 55 (1), 17-23.
106. Robert, J. and Jarry, C. (2003) J. Med. Chem., 46 (23), 4805-4817.